Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Cardiology

Understanding Your Subtype: Obstructive vs. Non-Obstructive HCM

At a Glance

Hypertrophic cardiomyopathy (HCM) is classified as either obstructive, where thickened heart muscle blocks blood flow, or non-obstructive, where the heart is stiff but flow isn't blocked. Your specific subtype dictates your symptoms and determines whether you need medications or surgery.

When you are diagnosed with Hypertrophic Cardiomyopathy, one of the first things your doctor will determine is whether your condition is obstructive or non-obstructive. This distinction is critical because it explains why you feel the way you do and dictates which treatments will work best for you [1][2].

Defining the “Blockage”

To understand these subtypes, you need to know three key terms that describe the “plumbing” of your heart:

  • Left Ventricular Outflow Tract (LVOT): This is the narrow path blood must travel to exit the heart’s main pumping chamber (the left ventricle) and enter the aorta to reach the rest of your body [3].
  • Systolic Anterior Motion (SAM): In some people with HCM, the thickened heart muscle causes the mitral valve (a heart valve) to be sucked forward during a heartbeat. This valve then acts like a swinging door that gets stuck in the “outflow tract,” partially blocking the blood [4][3].
  • Gradient: This is a measurement of the pressure difference caused by the blockage. The higher the “gradient,” the harder your heart has to work to push blood past the obstruction [5][6].

Obstructive HCM (HOCM)

Approximately two-thirds of people with HCM have the obstructive form [7].

  • The Threshold: Doctors define “obstructive” as having an LVOT gradient of 30 mmHg or higher [8][9].
  • Latent Obstruction: Some people have a low gradient at rest, but it spikes when they exercise or strain (like during a Valsalva maneuver). This is called “latent” or “provocable” obstruction [10][11].
  • Symptoms: Because the heart is fighting a physical blockage, patients with HOCM often experience significant shortness of breath, chest pain, and fainting, especially during activity [7][12].

Non-Obstructive HCM

In the non-obstructive subtype, the heart muscle is still thickened and stiff, but it does not physically block the blood from leaving the heart [5].

  • The Mechanism: Symptoms in non-obstructive HCM are usually caused by the heart’s inability to relax and fill with enough blood (diastolic dysfunction) rather than a blockage [13].
  • Symptoms: While there is no “plumbing” blockage, patients can still feel very fatigued or short of breath because the heart is “stiff” and inefficient [14][15].

How Treatment Paths Differ

Your subtype is the primary factor in deciding your treatment plan [2].

Treatment Goal Obstructive HCM (HOCM) Non-Obstructive HCM
Medication Focuses on slowing the heart and reducing the force of contraction to keep the “door” (mitral valve) from closing (e.g., beta-blockers, calcium channel blockers, or newer myosin inhibitors like mavacamten) [1][16]. Focuses on managing symptoms of heart failure and improving the heart’s ability to fill with blood [13][17].
Procedures If meds don’t work and the gradient is 50 mmHg or higher, doctors may suggest Septal Reduction Therapy (surgical myectomy or alcohol septal ablation) to physically thin the muscle and clear the path [18][19][20]. Invasive procedures to clear the outflow tract are generally not used because there is no physical blockage to remove [13].
Lifestyle Patients must be very careful with dehydration, as “empty” hearts are more likely to obstruct [21][22]. Patients are often encouraged to engage in structured, moderate exercise to improve overall fitness [23][24].

Knowing your subtype empowers you to understand why certain medications are prescribed and why your doctor may—or may not—be discussing surgery with you.

Return to Home

Common questions in this guide

What is the difference between obstructive and non-obstructive HCM?
In obstructive HCM, the thickened heart muscle physically blocks blood from leaving the heart. In non-obstructive HCM, there is no physical blockage, but the heart muscle is stiff and struggles to relax and fill with blood properly.
What is an LVOT gradient in hypertrophic cardiomyopathy?
An LVOT gradient measures the pressure difference caused by a blockage in your heart's outflow tract. Doctors consider HCM to be obstructive if this gradient is 30 mmHg or higher.
What does latent or provocable obstruction mean?
Latent obstruction means you might not have a heart blockage while resting, but it occurs when you exercise or strain. Doctors often use stress tests or breathing exercises to check for this hidden blockage.
How is obstructive HCM treated differently than non-obstructive HCM?
Obstructive HCM treatments focus on slowing the heart's contraction and potentially using surgery to clear the physical blockage. Non-obstructive HCM treatment focuses on improving the heart's ability to fill with blood and managing symptoms, usually without invasive procedures.
What is Systolic Anterior Motion (SAM)?
SAM happens when the thickened heart muscle pulls the mitral valve forward during a heartbeat. This causes the valve to act like a swinging door that gets stuck, partially blocking blood flow out of the heart.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I have obstructive (HOCM) or non-obstructive HCM, and what is my highest recorded LVOT gradient?
  2. 2.Was my gradient measured only at rest, or was it also measured during a 'provocative' test like exercise or the Valsalva maneuver?
  3. 3.Does my imaging show 'Systolic Anterior Motion' (SAM) of the mitral valve?
  4. 4.Based on my subtype, am I a candidate for the newer cardiac myosin inhibitor medications?
  5. 5.If my symptoms worsen, would you recommend septal reduction therapy (myectomy or ablation) or a change in medication first?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures.

    Banthiya S, Check L, Atkins J

    US cardiology 2024; (18()):e17 doi:10.15420/usc.2023.21.

    PMID: 39508003
  2. 2

    Current management of hypertrophic cardiomyopathy.

    Sikand N, Stendahl J, Sen S, et al.

    BMJ (Clinical research ed.) 2025; (389()):e077274 doi:10.1136/bmj-2023-077274.

    PMID: 40425241
  3. 3

    Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy.

    Teo EP, Teoh JG, Hung J

    Current opinion in cardiology 2015; (30(5)):475-82 doi:10.1097/HCO.0000000000000200.

    PMID: 26192489
  4. 4

    Systolic anterior motion after mitral valve repair: where do we stand in 2015?

    Alfieri O, Lapenna E

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2015; (48(3)):344-6 doi:10.1093/ejcts/ezv230.

    PMID: 26142473
  5. 5

    Differences in the Impact of Left Ventricular Outflow Tract Obstruction on Intraventricular Pressure Gradient in Feline Hypertrophic Cardiomyopathy.

    Hirose M, Watanabe M, Takeuchi A, et al.

    Animals : an open access journal from MDPI 2024; (14(22)) doi:10.3390/ani14223320.

    PMID: 39595372
  6. 6

    Myocardial Bridge or Something Else?

    Wang X, Rastegar H, Rowin EJ, et al.

    Journal of cardiothoracic and vascular anesthesia 2022; (36(1)):332-337 doi:10.1053/j.jvca.2021.08.010.

    PMID: 34474950
  7. 7

    Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.

    Liang LW, Lumish HS, Sewanan LR, et al.

    Journal of cardiac failure 2024; (30(9)):1136-1153 doi:10.1016/j.cardfail.2024.04.024.

    PMID: 38777216
  8. 8

    Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy.

    Arslan F, Akdim F, Ten Berg JM

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2021; (97(3)):488-492 doi:10.1002/ccd.29178.

    PMID: 32808736
  9. 9

    Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.

    Nakamura T, Iwanaga Y, Yasuda M, et al.

    The international journal of cardiovascular imaging 2016; (32(4)):613-20 doi:10.1007/s10554-015-0806-8.

    PMID: 26589516
  10. 10

    Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy.

    Kumar S, Van Ness G, Bender A, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(7)):791-798 doi:10.1016/j.echo.2018.01.022.

    PMID: 29573929
  11. 11

    Left ventricular stent-graft implantation for severe left ventricular outflow tract obstruction after transcatheter mitral valve implantation.

    Ruge H, Krane M

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2024; (66(2)) doi:10.1093/ejcts/ezae305.

    PMID: 39120113
  12. 12

    Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Olivotto I, Oreziak A, Barriales-Villa R, et al.

    Lancet (London, England) 2020; (396(10253)):759-769 doi:10.1016/S0140-6736(20)31792-X.

    PMID: 32871100
  13. 13

    Conduction block and thin and hypokinetic myocardial segments in feline hypertrophic cardiomyopathy.

    Sung Y, Park J, Chae Y, et al.

    Veterinarni medicina 2025; (70(8)):302-306 doi:10.17221/14/2025-VETMED.

    PMID: 40995508
  14. 14

    Cardiac pacing in patients with hypertrophic obstructive cardiomyopathy.

    Tolosana JM, Trucco E

    Global cardiology science & practice 2018; (2018(3)):29 doi:10.21542/gcsp.2018.29.

    PMID: 30393641
  15. 15

    Altered coronary artery function, arteriogenesis and endothelial YAP signaling in postnatal hypertrophic cardiomyopathy.

    Langa P, Marszalek RJ, Warren CM, et al.

    Frontiers in physiology 2023; (14()):1136852 doi:10.3389/fphys.2023.1136852.

    PMID: 37064918
  16. 16

    Cardiac myosin inhibitors in hypertrophic cardiomyopathy.

    Lim J, Kim HK

    Journal of cardiovascular imaging 2025; (33(1)):7 doi:10.1186/s44348-025-00052-7.

    PMID: 40624601
  17. 17

    Interventions in Hypertrophic Obstructive Cardiomyopathy.

    Ding WY, Meah MN, Stables R, Cooper RM

    The Canadian journal of cardiology 2024; (40(5)):833-842 doi:10.1016/j.cjca.2023.12.001.

    PMID: 38070769
  18. 18

    Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.

    Zhou M, Ta S, Hahn RT, et al.

    JAMA cardiology 2022; (7(5)):529-538 doi:10.1001/jamacardio.2022.0259.

    PMID: 35353129
  19. 19

    Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.

    Desai MY, Owens A, Geske JB, et al.

    Circulation 2023; (147(11)):850-863 doi:10.1161/CIRCULATIONAHA.122.062534.

    PMID: 36335531
  20. 20

    Alcohol septal ablation: A useful tool in our arsenal against hypertrophic obstructive cardiomyopathy.

    Savarimuthu S, Harky A

    Journal of cardiac surgery 2020; (35(8)):2017-2024 doi:10.1111/jocs.14815.

    PMID: 32652778
  21. 21

    Prognosis of Patients with Hypertrophic Obstructive Cardiomyopathy: A Multicenter Cohort Study with Data-Driven Propensity Score Matching Analysis.

    He Y, Ma H, Sun N, et al.

    Reviews in cardiovascular medicine 2023; (24(9)):267 doi:10.31083/j.rcm2409267.

    PMID: 39076388
  22. 22

    Conventional cardiopulmonary resuscitation-induced refractory cardiac arrest due to latent left ventricular outflow tract obstruction due to a sigmoid septum: a case report.

    Yamagishi T, Tanabe T, Fujita H, et al.

    Journal of medical case reports 2018; (12(1)):229 doi:10.1186/s13256-018-1767-z.

    PMID: 30122151
  23. 23

    Exercise training in hypertrophic cardiomyopathy: a meta-analysis of randomised trials with trial sequential analysis.

    Correia VM, Morales Ribeiro V, Henkes Machado R, et al.

    Heart (British Cardiac Society) 2025; doi:10.1136/heartjnl-2025-326377.

    PMID: 41320293
  24. 24

    Randomized Controlled Trial of Moderate- and High-Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy: Effects on Fitness and Cardiovascular Response to Exercise.

    MacNamara JP, Dias KA, Hearon CM, et al.

    Journal of the American Heart Association 2023; (12(20)):e031399 doi:10.1161/JAHA.123.031399.

    PMID: 37830338

This page explains hypertrophic cardiomyopathy (HCM) subtypes for educational purposes only. Always consult your cardiologist to understand your specific diagnosis, LVOT gradients, and treatment options.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.